Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates
Krystal Biotech (KRYS) delivered earnings and revenue surprises of +5.29% and +0.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?